Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Biomarker Prospects May Be Unrealistic, At Least For Now

Executive Summary

The high hopes for genomics and proteomics research to yield valid cancer biomarkers may exceed the field's current capabilities, David Ransohoff (University of North Carolina) cautioned at the Institute of Medicine's National Cancer Policy Forum

You may also be interested in...

FDA To Provide Updates On Critical Path Opportunities List Projects

FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16

Biomarkers To Get Individual Guidances Under FDA Plan To Promote Development

As part of a strategy to encourage biomarker qualification, FDA is prepared to issue guidances on the use of specific biomarkers

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts